FDA Accepts and Grants Priority Review of Vanda's Applications for HETLIOZ® (tasimelteon) in the Treatment of Smith-Magenis Syndrome
Go back to FDA Accepts and Grants Priority Review of Vanda's Applications for HETLIOZ® (tasimelteon) in the Treatment of Smith-Magenis Syndrome| Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) | Delayed: 5.98 -0.02 (0.33%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $6.00 | 52 Week High | $18.00 | |||
| Open | $5.97 | 52 Week Low | $6.91 | |||
| Day High | $6.11 | P/E | N/A | |||
| Day Low | $5.96 | EPS | $-0.67 | |||
| Volume | 228,821 | |||||
